HNL Genomics (CTGT) holds a New York State Department of Health Clinical Laboratory Permit to perform molecular genetic testing on patients from New York State. Currently, our osteogenesis imperfecta tests have been approved and may be run on all New York state patients. For all other tests, a Restricted Laboratory Permit must be obtained before HNL Genomics (CTGT) can perform the test on a New York state patient. Additional tests for New York state patients will be added when they are approved by the New York State Department of Health.

To order osteogenesis imperfecta testing on New York state patients, a Patient Consent Form must be completed and submitted to HNL Genomics (CTGT) with the patient specimen.

Additionally, HNL Genomics' (CTGT) standard Test Requisition Form should be completed and submitted with the patient specimen.

The following panels are approved for New York State patients:

(Please note: The MBTPS2 and XYLT2 genes are not included in the New York State Approved test.)

Additionally, the following osteogenesis imperfecta related genes are approved for single gene testing and targeted variant/known familial mutation testing:



To perform any other test on a New York State patient, a Non-Permitted Laboratory Test Request Approval Form must be completed and submitted to the New York State Department of Health. If the request is approved, HNL Genomics (CTGT) can perform the test for that patient. Please submit a copy of the approval letter and the HNL Genomics (CTGT) standard Test Requisition Form with the patient specimen. For further information on the approval process, please see the NYS Instructions and NYS Non-Permitted Laboratory Test Request Approval Form.

NYS Instructions                            NYS Non-Permitted Laboratory Test Request Approval Form

The American Medical Association (AMA) Current Procedural Terminology (CPT) codes published by HNL Lab Medicine are guidelines and are intended for informational purposes only. CPT coding is the exclusive responsibility of the billing entity. HNL Lab Medicine strongly recommends confirmation of CPT codes with third-party payors and/or the AMA. We assume no responsibility for billing errors due to reliance upon CPT codes provided by HNL Lab Medicine.


October 28, 2022

Non-Hodgkin Lymphoma FISH Panel Now Available

B-cell lymphoma is a large group of heterogenous disorders and comprises a majority of non-Hodgkin lymphomas.
Read More
October 20, 2022

Genetic testing for Familial Transthyretin Amyloidosis (TTR) NOW AVAILABLE In-House

Hereditary amyloidosis is a life-threatening disorder that can lead to peripheral neuropathy and heart failure.
Read More
August 08, 2022

Familial hypercholesterolemia (FH)

Familial hypercholesterolemia (FH) is a genetic disorder that increases the likelihood of having coronary heart disease at a younger age. Learn about how to determine if you have hypercholesterolemia and what actions you can take to create better outcomes!

Read More
April 11, 2022

Genome Sequencing: A Vital Tool Used in Identifying and Tracking New COVID-19 Variants

Genome sequencing is reading or decoding the complete genetic information i.e. “Genome” of an organism that is encrypted in the form of a very long string called DNA made up of 4 letters, A, T, G, and C. The genome of an organism essentially determines their physical characteristics and ...
Read More
March 03, 2022

The Effect of Genetics on Individual Heart Health: Early Identification of FH Variations to Optimize Treatment

Test must be ordered by a Physician.

Familial hypercholesterolemia (FH) is a genetic disorder that is characterized by abnormally high blood levels of low-density lipoprotein (LDL) cholesterol, sometimes referred to as "bad cholesterol". This condition affects an estimated 1 in 250 people, and increases the likelihood of developing cardiovascular disease. In fact, FH is estimated to be the cause of 2-3% of heart attacks in individuals younger than age 60.

Read More